Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Date publication

février 2016

Journal

Lancet (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HERBRECHT Raoul

Tous les auteurs :
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26684607

Résumé

Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease.

Mots clés

Administration, Oral, Adult, Aged, Antifungal Agents, administration & dosage, Aspergillosis, drug therapy, Double-Blind Method, Drug Administration Schedule, Female, Humans, Injections, Intravenous, Male, Middle Aged, Mycoses, drug therapy, Nitriles, administration & dosage, Pyridines, administration & dosage, Treatment Outcome, Triazoles, administration & dosage, Voriconazole, administration & dosage

Référence

Lancet. 2016 Feb;387(10020):760-9